1. Generics Bulletin
  2. >>Business
  3. >>Deals

Akorn Sharpens Focus As It Divests Ophthalmic Brands

Focusing On Human Generics And Animal Care After Completing Sale To Théa Pharma

 
• By Dave Wallace

Akorn says it is concentrating its focus on “targeted avenues of growth” – including human generics and animal care – after divesting its branded ophthalmic portfolio to Théa Pharma.

Glasses Eye Test Chart Vision Focus
Akorn is sharpening the focus of its business with the divestment of its ophthalmic brands • Source: David Izquierdo Roger / Alamy Stock Photo

Akorn says the completed divestment of its branded ophthalmic portfolio to Théa Pharma will enable the firm to focus on growth areas including human generics and animal care.

Financial details were not revealed of the transaction, which follows Akorn going through Chapter 11 bankruptcy proceedings and a sale...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Intas Expands Its Plasma Business With A European Acquisition

 
• By Urtė Fultinavičiūtė

Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 
• By Urtė Fultinavičiūtė

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By Dave Wallace

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

Civica Pairs With Fresenius Kabi To Supply Stelara Biosimilar

 
• By Dave Wallace

US non-profit Civica has announced a partnership with Fresenius Kabi to supply a Stelara rival, revealing pricing details for its exclusive unbranded version of Kabi’s Otulfi biosimilar that will be available from the start of next year.

More from Business

Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3

 
• By Dean Rudge

Viatris is conducting a company-wide strategic review to boost long-term competitiveness, targeting cost savings and a shift to complex, high-margin products. CEO Scott Smith says it’s timely after four divestitures. An update is due in the Q3 2025 earnings call in November.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 
• By Urtė Fultinavičiūtė

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By Dean Rudge

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.